Complete Genomics Reports Up to $4.3M in Preliminary Q3 Revenue; Ups IPO Target by $10M; Prices Shares | GenomeWeb

By Julia Karow

Complete Genomics this week reported up to $4.3 million in preliminary revenue for the third quarter, as the firm increased the target for its planned initial public offering by about $10 million and priced its shares.

For the quarter ended Sept. 30, Complete Genomics recorded between $3.9 million and $4.3 million in revenue, representing sales to approximately 20 customers, according to an amendment of its S-1 filing with the Securities and Exchange Commission.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.